

A&I

ANÄSTHESIOLOGIE & INTENSIVMEDIZIN

Offizielles Organ: Deutsche Gesellschaft für Anästhesiologie und Intensivmedizin e. V. (DGAI)
Berufsverband Deutscher Anästhesistinnen und Anästhesisten e. V. (BDA)

Organ: Deutsche Interdisziplinäre Vereinigung für Intensiv- und Notfallmedizin e. V. (DIVI)



Argininosuccinate Lyase Deficiency

orphan**anesthesia**

a project of the German Society
of Anaesthesiology and Intensive Care Medicine

SUPPLEMENT NR. 3 | 2025

OrphanAnesthesia –

ein krankheitsübergreifendes Projekt des Wissenschaftlichen Arbeitskreises Kinderanästhesie der Deutschen Gesellschaft für Anästhesiologie und Intensivmedizin e.V.

Ziel des Projektes ist die Veröffentlichung von Handlungsempfehlungen zur anästhesiologischen Betreuung von Patientinnen und Patienten mit seltenen Erkrankungen. Damit will OrphanAnesthesia einen wichtigen Beitrag zur Erhöhung der Patientensicherheit leisten.

Patientinnen und Patienten mit seltenen Erkrankungen benötigen für verschiedene diagnostische oder therapeutische Prozeduren eine anästhesiologische Betreuung, die mit einem erhöhten Risiko für anästhesieassoziierte Komplikationen einhergehen. Weil diese Erkrankungen selten auftreten, können Anästhesistinnen und Anästhesisten damit keine Erfahrungen gesammelt haben, sodass für die Planung der Narkose die Einholung weiterer Information unerlässlich ist. Durch vorhandene spezifische Informationen kann die Inzidenz von mit der Narkose assoziierten Komplikationen gesenkt werden. Zur Verfügung stehendes Wissen schafft Sicherheit im Prozess der Patientenversorgung.

Die Handlungsempfehlungen von OrphanAnesthesia sind standardisiert und durchlaufen nach ihrer Erstellung einen Peer-Review-Prozess, an dem eine Anästhesistin bzw. ein Anästhesist sowie eine weitere Krankheitsexpertin bzw. ein weiterer Krankheitsexperte (z. B. Pädiaterin bzw. Pädiater oder Neurologin bzw. Neurologe) beteiligt sind. Das Projekt ist international ausgerichtet, sodass die Handlungsempfehlungen grundsätzlich in englischer Sprache veröffentlicht werden.

Ab Heft 5/2014 werden im monatlichen Rhythmus je zwei Handlungsempfehlungen als Supplement der A&I unter www.ai-online.info veröffentlicht. Als Bestandteil der A&I sind die Handlungsempfehlungen damit auch zitierfähig. Sonderdrucke können gegen Entgelt bestellt werden.

OrphanAnesthesia –

a project of the Scientific Working Group of Paediatric Anaesthesia of the German Society of Anaesthesiology and Intensive Care Medicine

The target of OrphanAnesthesia is the publication of anaesthesia recommendations for patients suffering from rare diseases in order to improve patients' safety. When it comes to the management of patients with rare diseases, there are only sparse evidence-based facts and even far less knowledge in the anaesthetic outcome. OrphanAnesthesia would like to merge this knowledge based on scientific publications and proven experience of specialists making it available for physicians worldwide free of charge.

All OrphanAnesthesia recommendations are standardized and need to pass a peer review process. They are being reviewed by at least one anaesthesiologist and another disease expert (e.g. paediatrician or neurologist) involved in the treatment of this group of patients.

The project OrphanAnesthesia is internationally oriented. Thus all recommendations will be published in English.

Starting with issue 5/2014, we'll publish the OrphanAnesthesia recommendations as a monthly supplement of A&I (Anästhesiologie & Intensivmedizin). Thus they can be accessed and downloaded via www.ai-online.info. As being part of the journal, the recommendations will be quotable. Reprints can be ordered for payment.

**Bisher in A&I publizierte
Handlungsempfehlungen finden
Sie unter:**

www.ai-online.info/Orphsuppl
www.orphananesthesia.eu

**Find a survey of the recommendations
published until now on:**

www.ai-online.info/Orphsuppl
www.orphananesthesia.eu

Projektleitung

Prof. Dr. Tino Münster, MHBA

Chefarzt
Klinik für Anästhesie und
operative Intensivmedizin
Krankenhaus Barmherzige
Brüder Regensburg
Prüfeninger Straße 86
93049 Regensburg,
Deutschland
Tel.: 0941 369-2350

E-Mail: Tino.Muenster@barmherzige-regensburg.de

orphan^aesthesia

Anaesthesia recommendations for patients suffering from

Argininosuccinate Lyase Deficiency

Disease name: Argininosuccinate lyase deficiency

ICD 10: E72.2

Synonyms: ASA deficiency, ASL deficiency, argininosuccinase deficiency, argininosuccinate lyase deficiency, argininosuccinic acid lyase deficiency

Disease summary:

Defect:

Argininosuccinate lyase (ASL) deficiency, also known as argininosuccinic aciduria (AA), is the result of a mutated or deficient argininosuccinate lyase enzyme. This defective or deficient enzyme leads to inadequate ureagenesis, accumulation of argininosuccinic acid, and deficient endogenous arginine production. Aside from the hyperammonaemia pervasive to urea cycle disorders as a group, ASL deficiency is specifically associated with higher rates of neurocognitive deficits, liver disease, trichorrhexis nodosa (coarse brittle hair), impairment of creatinine clearance, chronic diarrhea, and systemic hypertension. Electrolyte imbalances of unclear aetiology have been identified, even in patients not treated with nitrogen scavenging drugs. This may be due to increased renal wasting. Nitrogen-scavenging therapy (e.g., with sodium benzoate or sodium phenyl butyrate) may lead to hypernatraemia and hypokalaemia. Like other urea cycle disorders, this disease is of rare occurrence, with incidences of approximately 1/70,000. ASL deficiency is passed via autosomal recessive inheritance, and may manifest in one of two forms: a neonatal onset disease or a less severe late-onset form of the disease.

Medicine in progress



Perhaps new knowledge

Every patient is unique

Perhaps the diagnostic is wrong



Find more information on the disease, its centres of reference and patient organisations on Orphanet: www.orpha.net

► **Citation:** Sisk PM, Scales L, Polan MB: Argininosuccinate Lyase Deficiency. Anästh Intensivmed 2025;66:S78–S87. DOI: 10.19224/ai2025.S078

Emergency information

A	AIRWAY / ANAESTHETIC TECHNIQUE	Typical airway difficulties / anomalies / malformations? (Dis)Advantage for general (GA) or regional anaesthesia? (RA)
B	BLOOD PRODUCTS (COAGULATION)	Special preparation / storage of blood products necessary? Special haemostaseologic tests / consideration necessary? Coagulation disorders / pathologies?
C	CIRCULATION	Typical cardiopulmonary malformations, pathologies, arrhythmias...? Congenital heart disease/ anomaly? Special risk for heart failure? Haemodynamic specifics / risks?
D	DRUGS	Any drugs that should be avoided? Interactions with typical home medication? Special recommendations for premedication? Risk for MH/rhabdomyolysis?
E	EQUIPMENT	Special equipment (or care / assistance) needed for e.g., transport or within PACU/ IMC/ ICU?

Disease summary

Pathophysiology:

The urea cycle is a hepatic pathway, which converts excess nitrogen to urea. Urea is then excreted via renal pathways. As the breakdown of protein results in an increased nitrogen burden, urea cycle metabolism increases during physiologic states predominated by catabolism. Stressors such as sepsis, surgery, fasting, high-protein meal consumption and heavy exercise may all induce catabolic metabolism.

If the urea cycle is impaired, nitrogen will accumulate in the form of ammonia. Hyperammonaemia may be harmful to multiple organ systems. This may be particularly damaging to the neurocognitive system. Significant hyperammonaemia may lead to encephalopathy associated with vomiting, lethargy, seizure, central respiratory depression and death.

Aside from the hyperammonaemia that results from inadequate ureagenesis, patients with ASL deficiency experience symptoms related to decreased endogenous arginine and increased argininosuccinic acid. Human hair contains more than 10% arginine by weight. Without supplementation, patients exhibit weak brittle hair which is often surrounded by some degree of alopecia. Arginine deficiency may also cause systemic hypertension due to a secondarily reduced synthesis of nitric oxide. Conversely, excess argininosuccinic acid may be accountable for the liver disease observed in some ASL-deficient patients. In addition, specific neurocognitive deficits (including increased incidence of ADHD and seizure activity) are associated with the disorder, the pathophysiology of which remains unclear at this time.

Presentation:

The neonatal-onset disease is clinically more severe, and presents similarly to other urea cycle disorders with hyperammonaemia of acute concern. Neonates are often asymptomatic for the first 24-48 hours, before exhibiting lethargy, vomiting and feeding difficulties. Neonates initially present with tachycardia and tachypnoea, which progress to respiratory depression, seizures and death as ammonia accumulates. In the early stages of the disease, ASL deficiency may be difficult to distinguish from other commonly presenting urea cycle disorders. However, specific of ASL deficiency, cases of neonatal onset may exhibit the hallmark manifestations of liver disease or trichorrhexis nodosa. Alternatively, the late-onset variant of the disease is characterised by transient hyperammonaemia. Triggers may include stress, infection, dietary changes or any other event resulting in a predominately catabolic state.

Management:

Long-term management focuses on the prevention of metabolic crises by way of significant lifestyle modification in association with exogenous arginine supplementation. Such lifestyle modifications demand strict adherence to a stable diet that restricts protein and avoids fasting in an attempt to maintain anabolism. Metabolic decompensations resulting in hyperammonaemia require immediate medical attention. If medical management fails to normalise ammonia levels, haemodialysis may be required. Orthotopic liver transplantation may be considered if patients with recurrent decompensation are resistant to medical therapy.

Prognosis:

Due to the rarity of the disease and variable presentation, prognosis is difficult to assess. In general, life expectancy is decreased, with over 65% of long-term survival (Baruteau et al 2017) 80% of patients expiring before reaching an age of 20 years, regardless of the age at onset of disease. The implementation of new treatment strategies has resulted in greater survival rates in infants affected by the neonatal onset disease. However, this increase in survival is associated with a significant increase in mental disability.

Centres

Surgery should only be carried out in centres prepared for dealing with acute hyperammonaemic decompensations and should not be performed in the outpatient setting.

Typical surgery

- ENT procedures (bilateral myringotomy tubes, tonsillectomy and adenoidectomy) may be performed to decrease the risk of recurrent infections leading to metabolic crisis.
- General surgery procedures such as gastrostomy tube placement, anti-reflux procedures such as Nissen fundoplication and vascular access procedures are all common.
- Dental procedures under anaesthesia may be required due to developmental delay
- Anaesthesia for diagnostic procedures such as CT or MRI may be necessary
- Emergency procedures such as appendectomy or trauma surgery
- Some children may require liver transplant for recurrent hyperammonaemia and/or liver failure.

Type of anaesthesia

- There are insufficient data to support the superiority of any particular anaesthetic agent or technique.
- Induction:
 - Sevoflurane, sodium thiopental, isoflurane, propofol and nitrous oxide have all been reported to be safe for induction of anaesthesia in other urea cycle disorders.
- Maintenance:
 - Sevoflurane, isoflurane, nitrous oxide have been safely used for maintenance of anaesthesia in other urea cycle disorders.
 - Midazolam, s-ketamine, fentanyl and morphine in combination with surgical infiltration of ropivacaine have been reported as safe anaesthetic agents in other urea cycle disorders.
 - Pancuronium, atracurium, cisatracurium and vecuronium have been used without prolongation of neuromuscular blockade in other urea cycle disorders.
- Drugs that induce catabolism such as dexamethasone or other steroids should be avoided.
- Any anaesthetic agent should be used with caution and vigilant post-operative monitoring as the stress of surgery alone may trigger a metabolic crisis.
- ENT or dental procedures with potential bleeding into the GI tract should utilise OG tubes and/or throat packs to minimise the amount of blood ingested as this protein load may represent a metabolic stressor leading to decompensation.
- General anaesthesia should be used with caution and appropriate post-operative monitoring in conjunction with a clinical geneticist or metabolic physician.

Necessary additional diagnostic procedures (pre-operative)

- The following laboratory values should be evaluated pre-operatively:
 - Blood glucose

- Serum electrolytes
 - Patients may experience hypernatraemia and hypokalaemia
 - More common in patients receiving sodium phenylbutyrate or sodium benzoate therapy
- Plasma ammonia
 - Serves as a direct indicator of toxicity
- Liver function tests
- Coagulation studies
 - Patients with ASL deficiency are predisposed to hepatic dysfunction with resultant disruption of coagulation pathways.
- Arterial or venous blood gas may be considered.

Particular preparation for airway management

There are no specific recommendations or disease-related concerns regarding airway management.

Particular preparation for transfusion or administration of blood products

There are no specific recommendations for the transfusion of blood products.

Particular preparation for anticoagulation

Patients with argininosuccinate lyase deficiency do not routinely require anticoagulation.

Particular precautions for positioning, transport or mobilisation

There are no specific recommendations or disease-related concerns regarding the positioning of these patients.

Probable interaction between anaesthetic agents and patients' long-term medication

No specific interactions between maintenance medications and routine anaesthetic medications exist. Iatrogenic hypernatraemia should be avoided as Sodium containing IV fluids and sodium benzoate in addition to maintenance sodium phenylbutyrate represent a significant sodium burden. 1g sodium benzoate contains 7mmol sodium and 1g phenylbutyrate contains 5.4mmol sodium. Long-term medications should be maintained before and after surgery with conversion to IV formulations if necessary.

Anaesthetic procedure

- Involve a clinical geneticist or metabolic physician in advance for pre-operative planning
 - Patients routinely take sodium phenylbutyrate or glycerol phenylbutyrate or/and sodium benzoate (ammonia scavengers) and arginine (substrate for urea cycle metabolism beyond the deficient enzyme).

www.orphananesthesia.eu

5

- Glycerol phenylbutyrate is a clear liquid medication and may be taken pre-operatively prior to elective surgery.
 - Ammonia scavenging medication should not be applied prior to elective surgery
- Elective surgery should not be performed in the outpatient setting.
 - Patients should not fast for prolonged periods.
 - Patients should be the first case on the surgical schedule.
- Labs:
 - Blood glucose
 - Serum electrolytes
 - Plasma ammonia
 - Serves as a direct indicator of toxicity
 - Liver function tests
 - Coagulation studies
 - Patients with ASL deficiency are predisposed to hepatic dysfunction with resultant disruption of coagulation pathways.
- Identify catabolic stressors (e.g., infection, trauma, etc.)
 - Treat aggressively
- Avoid intraoperative hypothermia
- Minimise protein intake
- Optimise hydration
 - The night before surgery, 10% glucose solution with electrolytes should be infused at a rate that ensures anabolic metabolism.
 - This solution should be continued until the patient is known to be tolerating enteral nutrition.
- Minimise catabolic metabolism
 - The patient should preferably be kept in a state of anabolic metabolism.
- Promote nitrogen excretion
- It has been suggested to avoid prophylactic anti-emetic therapy as nausea and vomiting are an early sign of metabolic decompensation [9].
- Rapid extubation is recommended in order to facilitate evaluation of consciousness, nausea and vomiting as signs of metabolic decompensation.

Particular or additional monitoring

Electrolytes, ammonia levels and blood glucose should be evaluated pre-operatively. For prolonged procedures, intra-operative monitoring of arterial or venous blood gas, glucose and ammonia levels should be considered.

Possible complications

Patients are prone to life-threatening hyperammonaemia which may progress to coma, brain damage and death within hours.

Post-operative care

- Patients should be observed post-operatively for signs of hyperammonaemia in coordination with a clinical geneticist or metabolic physician.
- Arterial or venous blood gas, electrolytes and serum ammonia should be evaluated post-operatively every 6 hours during the first 24 hours

- These labs should also be checked if the patient experiences signs of metabolic decompensation such as vomiting, lethargy, tachypnoea or seizures.
- IV fluids containing glucose should be continued until the patient tolerates enteral nutrition.
- Oral feeds should be resumed as soon as possible to ensure optimal caloric intake and anabolic metabolism.
- In the first 24 hours post-op, it is recommended to follow the emergency regimen prescribed for times of metabolic stress (such as surgery, infection, vomiting or diarrhoea).
- In the following days, proteins can be introduced progressively.
 - IV glucose administration should stop only when the patient is well and metabolically stable.
- If there is intolerance of feeding, lipids must be added to the IV solution.
- Ambulatory surgery is not recommended.

Information about emergency-like situations / Differential diagnostics

- Patients are prone to life-threatening hyperammonaemia which may progress to coma, brain damage and death within hours
 - This may be triggered by:
 - Fasting
 - Poor feeding
 - Surgical stress
 - Hypothermia
 - Minor infections
 - Mild dehydration
 - Vomiting/diarrhoea
 - Non-compliance with medication
 - Corticosteroids
 - Non-compliance with diet
 - High protein intake
 - Failure to take metabolic formula mix or low-energy intake
 - Signs of metabolic crisis include:
 - Anorexia
 - Nausea/vomiting
 - Lethargy
 - Abnormal respiratory pattern
 - Spasticity
 - Hyperreflexia/clonus
- A clinical geneticist or metabolic physician should be contacted immediately if signs of metabolic crisis are present.
 - Recommended work-up:
 - Evaluate and treat any triggers
 - Check STAT ammonia level
 - Check CBC, CMP, ABG
 - Emergency treatment:
 - Cease all protein intake
 - Patient should be made NPO
 - Generous IV hydration to correct dehydration
 - IV normal saline boluses
 - Avoid lactated Ringer solutions

- Maintenance IVF with fluids containing D10% (or greater) at 1.5x maintenance rate
- Start IV intralipid therapy
- IV ammonia scavenger (Ammonul) therapy and IV arginine
- Acidosis may be corrected slowly with sodium bicarbonate
- Critically high ammonia levels ($>400\mu\text{mol/L}$ in children and $>200\mu\text{mol/L}$ in adults) may require emergency dialysis

Ambulatory anaesthesia

Ambulatory surgery should not be performed in patients with argininosuccinate lyase deficiency due to the possibility of surgical stress triggering a metabolic crisis which may not present until the post-operative period.

Obstetrical anaesthesia

Successful pregnancy has been described in patients suffering from argininosuccinate lyase deficiency [13]. There is no evidence to support the superiority of regional or general anaesthesia in these patients. Choice of anaesthetic technique should be dictated by the clinical situation. Clinical geneticists or metabolic physicians should be involved early in the pre-natal care of these patients. Patients should be monitored for signs of metabolic crisis throughout labour, delivery and the post-partum period. Involution of the post-partum uterus may trigger protein catabolism and metabolic decompensation. Anabolic metabolism should be ensured during delivery and the post-partum period. Glucose containing IV solutions should be maintained until tolerance of feeding has been documented.

Literature and internet links

1. Erez A, Nagamani S, Lee B. Argininosuccinate lyase deficiency-Argininosuccinic aciduria and beyond. *Am J Med Genet C: Semin Med Genet* 2011;157,pp.45-53
2. Baruteau J, Waddington SN, Alexander IE, Gissen P. Gene therapy for monogenic liver diseases: clinical successes, current challenges and future prospects. *J Inher Metab Dis* 2017;40,497-517. doi:10.1007/s10545-017-0053-3
3. Brusilow SW, Horwich AL. Online Metabolic and Molecular Basis of Inherited Disease 2009
4. Tuchman M, Lee B, Lichter-Konecki U, Summar ML, Yudkoff M, Cederbaum SD, Kerr DS, DiazGA, Seashore MR, Lee HS, McCarter RJ, Krischer JP, Batshaw ML. Cross-sectional multicenter study of patients with urea cycle disorders in the United States. *Mol Genet Metab* 2008;94:397-402
5. Fichtel JC, Richards JA, Davis LS. Trichorrhexis nodosa secondary to argininosuccinic aciduria. *Pediatr Dermatol* 2007;24:25-7
6. Erez A, Nagamani S, Shchelochkov O, Premkumar M, Campeau P, Chen Y, Garg H, Li L, Mian A, Bertin T, Black J, Zeng H, Tang Y, Reddy A, Summar M, O'Brien, W, Harrison D, Mitch W, Marini J, Aschner, J., Bryan, N. and Lee, B. Requirement of argininosuccinate lyase for systemic nitric oxide production. *Nature Medicine* 2011;17,1619-1626
7. Mori T, Nagai K, Mori M, Nagao M, Imamura M, Iijima M, Kobayashi K. Progressive liver fibrosis in late-onset argininosuccinate lyase deficiency. *Pediatr Devel Pathol* 2002;5:597-601
8. Bachmann C. Outcome and survival of 88 patients with urea cycle disorders: a retrospective evaluation. *Eur J Pediatr* 2003;162:410-416
9. Dudoit, et al. Anesthetic implications of ornithine transcarbamylase deficiency. *Pediatr Anaesth* 2010;20:666-673
10. Häberle J, Boddart N, Burlina A, Chakrapani A, Dixon M, Huemer M, Dionisi-Vici C. Suggested guidelines for the diagnosis and management of urea cycle disorders. *Orphanet Journal of Rare Diseases* 2012;7(32). doi:10.1186/1750-1172-7-32
11. Schmidt J, Kroeber S, Irouschek A, Birkholz T, Schroth M, Albrecht S. Anesthetic management of patients with ornithine transcarbamylase deficiency. *Pediatric Anesthesia* 2006;16(3),333-337. doi:10.1111/j.1460-9592.2005.01695.x
12. Schmidt J, et al. Anesthetic management of patients with ornithine transcarbamylase deficiency. *Paediatr Anaesth* 2006;16:333-337
13. Madarch MR, Roe K, Cederbaum SD. Successful pregnancy outcome in a woman with argininosuccinate lyase deficiency. *J Inher Metab Dis* 1999,102-106. Retrieved October 3, 2017, from <https://link.springer.com/content/pdf/10.1023%2FA%3A1005481431955.pdf>.
14. Ficicioglu C, Mandell R, Shih VE. Argininosuccinate lyase deficiency: long-term outcome of 13 patients detected by newborn screening. *Mol Genet Metab* 2009;98:273-7
15. Naganami, et al. Argininosuccinate lyase deficiency. *Genet Med. GeneReviews*. 2012;14:501-7.

Last date of modification: December 2017

These guidelines have been prepared by:

Authors

Joseph M. Sisk, Assistant Professor of Pediatric Anesthesiology, Assistant Program Director, Pediatric Anesthesiology Fellowship, The Children's Hospital at OU Medical Center

Laci Scales, Medical Student, University of Oklahoma College of Medicine

Michelle B. Polan, Clinical and Medical Biochemical Geneticist, University of Oklahoma Health Science Center, USA

Peer revision 1

Cristina Del Rio Peña, Department of Paediatric Anaesthesia, 12 de Octubre Hospital, Madrid, Spain

Peer revision 2

Elena Martín-Hernández, Centro de Referencia Nacional para Enfermedades Metabólicas Hereditarias (C.S.U.R), Unidad Pediátrica de Enfermedades Raras. E. Mitocondriales-E. Metabólicas Hereditarias. Servicio de Pediatría Hospital Universitario 12 de Octubre. Universidad Complutense de Madrid. Edificio Materno Infantil, Madrid, Spain

Julien Baruteau, Genetics and Genomic Medicine Programme, UCL Great Ormond Street Institute of Child Health, London, United Kingdom

Herausgeber



DGAI

Deutsche Gesellschaft
für Anästhesiologie und
Intensivmedizin e. V.
Präsident: Prof. Dr. G. Marx,
Aachen



BDA

Berufsverband Deutscher
Anästhesistinnen und
Anästhesisten e. V.
Präsidentin: Prof. Dr.
G. Beck, Mannheim

Schriftleitung

Präsident/in der Herausgeberverbände

Gesamtschriftleiter/Editor-in-Chief:

Prof. Dr. Dr. Kai Zacharowski,
ML FRCA FESAIC, Frankfurt

Stellvertretender Gesamtschriftleiter/

Deputy Editor:

Prof. Dr. T. Volk, Homburg/Saar

CME-Schriftleiter/CME-Editor:

Prof. Dr. W. Zink, Ludwigshafen

Redaktionskomitee/Editorial Board

Priv.-Doz. Dr. E. Adam, Frankfurt

Prof. Dr. M. Adamzik, Bochum

Dr. J. Aulenkamp, Essen

Prof. Dr. G. Beck, Mannheim

Prof. Dr. T. Brenner, Essen

Prof. Dr. A. Brinkmann, Heidenheim

Prof. Dr. M. Coburn, Bonn

Prof. Dr. S.M. Coldewey, Jena

Prof. Dr. V. von Dossow, Bad Oeynhausen

Prof. Dr. B. Ellger, Dortmund

Prof. Dr. K. Engelhard, Mainz

Prof. Dr. M. Fischer, Göttingen

Prof. Dr. D. Fries, Innsbruck

Prof. Dr. K. Hahnenkamp, Greifswald

Prof. Dr. A.R. Heller, Augsburg

Prof. Dr. B. Jungwirth, Ulm

Prof. Dr. T. Loop, Freiburg

Prof. Dr. K. Meissner, Göttingen

Prof. Dr. W. Meißner, Jena

Prof. Dr. P. Meybohm, Würzburg

Prof. Dr. T. Müller-Wolff, Ludwigsburg

Prof. Dr. H. Mutlak, Offenbach

Prof. Dr. C. Nau, Lübeck

Priv.-Doz. Dr. V. Neef, Frankfurt

Prof. Dr. B. O'Brien, Berlin

Dr. B. Oehler, Heidelberg

Prof. Dr. S.G. Sakka, Koblenz

Prof. Dr. M. Sander, Gießen

Prof. Dr. B. Saugel, Hamburg

Prof. Dr. S. Schäfer, Oldenburg

Priv.-Doz. Dr. H. Schöchl, Salzburg

Prof. Dr. A. Steinbicker, Köln

Dr. M.T. Völker, Leipzig

Prof. Dr. N.-M. Wagner, Würzburg

Prof. Dr. F. Wappler, Köln

Prof. Dr. M. Weigand, Heidelberg

Redaktion/Editorial Staff

Korrespondenzadresse:

Neuwieder Straße 9 | 90411 Nürnberg |

Deutschland | Tel.: 0911 9337812

E-Mail: redaktion@ai-online.info

Verlag & Druckerei

Aktiv Druck & Verlag GmbH

An der Lohwiese 36 |

97500 Ebelsbach | Deutschland

www.aktiv-druck.de



Geschäftsführung

Wolfgang Schröder | Jan Schröder |

Nadja Schwarz

Tel.: 09522 943560 | Fax: 09522 943567

E-Mail: info@aktiv-druck.de

Anzeigen | Vertrieb

Pia Müller | Robert Kux

Tel.: 09522 943570 | Fax: 09522 943577

E-Mail: anzeigen@aktiv-druck.de

Verlagsrepräsentanz

Jürgen Distler

Neuwieder Straße 9 | 90411 Nürnberg

Tel.: 0171 9432534

E-Mail: jdistler@bda-ev.de

Herstellung | Gestaltung

Pia Müller | Robert Kux | Stefanie Triebert

Tel.: 09522 943570 | Fax: 09522 943577

E-Mail: ai@aktiv-druck.de

Titelbild

Gestaltung: Klaus Steigner

Paumgartnerstraße 28 | 90429 Nürnberg

E-Mail: mazyblue@klaus-steigner.de

www.klaus-steigner.de

Erscheinungsweise 2025

Der 66. Jahrgang erscheint jeweils zum
Monatsanfang, Heft 7/8 als Doppelausgabe.

Bezugspreise (inkl. Versandkosten):

• Einzelhefte	30,- €
• Jahresabonnement:	
Europa (ohne Schweiz)	258,- €
(inkl. 7 % MwSt.)	
Schweiz	266,- €
Rest der Welt	241,- €

Mitarbeiter aus Pflege, Labor, Studenten und Auszubildende (bei Vorlage eines entsprechenden Nachweises)

Europa (ohne Schweiz)	94,- €
(inkl. 7 % MwSt.)	
Schweiz	90,- €
Rest der Welt	94,- €

**Für Mitglieder der DGAI und/oder
des BDA ist der Bezug der Zeitschrift
im Mitgliedsbeitrag enthalten.**

Allgemeine Geschäfts- und Lieferbedingungen

Die allgemeinen Geschäfts- und Lieferbedingungen entnehmen Sie bitte dem Impressum auf www.ai-online.info

Indexed in **CINAHL; Current Contents®/ Clinical Medicine, EBSCO; EMBASE/ Excerpta Medica; Medical Documentation Service; Research Alert; Sci Search; Scopus; SUBIS Current Awareness in Biomedicine; VINITI; Russian Academy of Science.**

Nachdruck | Urheberrecht

Die veröffentlichten Beiträge sind urheberrechtlich geschützt. Jegliche Art von Vervielfältigungen – sei es auf mechanischem, digitalem oder sonst möglichem Wege – bleibt vorbehalten. Die Aktiv Druck & Verlags GmbH ist allein autorisiert, Rechte zu vergeben und Sonderdrucke für gewerbliche Zwecke, gleich in welcher Sprache, herzustellen. Anfragen hierzu sind nur an den Verlag zu richten. Jede im Bereich eines gewerblichen Unternehmens zulässig hergestellte oder benutzte Kopie dient gewerblichen Zwecken gem. § 54 (2) UrhG. Die Wiedergabe von Gebrauchsnamen, Handelsnamen, Warenbezeichnungen usw. in dieser Zeitschrift berechtigt auch ohne besondere Kennzeichnung nicht zu der Annahme, dass solche Namen im Sinne der Warenzeichen- und Markenschutz-Gesetzgebung als frei zu betrachten wären und daher von jedermann benutzt werden dürften.

Wichtiger Hinweis

Für Angaben über Dosierungsanweisungen und Applikationsformen kann vom Verlag und den Herausgebern keine Gewähr übernommen werden. Derartige Angaben müssen vom jeweiligen Anwender im Einzelfall anhand anderer Literaturstellen auf ihre Richtigkeit überprüft werden. Gleiches gilt für berufs- und verbandspolitische Stellungnahmen und Empfehlungen.

Die Beiträge aus der A&I
finden Sie online unter:
www.ai-online.info

CONTACT US

Please do not hesitate to contact us. We will be glad to answer and provide further information to you at any time.

.....
Name

.....
First Name

.....
Department / Hospital

.....
Place

.....
Telephone

.....
E-Mail

.....
Date / Signature

Please contact me for further information

☐

I would like to participate in the project

☐

ADDRESS

German Society of Anaesthesiology and
Intensive Care Medicine
Neuwieder Straße 9 | 90411 Nuremberg | Germany
Tel.: +49-911-933780
Email: info@orphananesthesia.eu